Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KRAS | P01116 | 8/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4410030 | 0.93 | LMNA (0.39) | TGFBR1ESR2NR1H2LMNATP53 | |
| SCHEMBL4406534 | 0.84 | ESR2 (0.40) | ESR2NR1H2TP53KRASRIPK1 | |
| SCHEMBL4408978 | 0.81 | USP30 (0.39) | TGFBR1TP53MAPTKRASUSP30 | |
| SCHEMBL4412331 | 0.81 | USP30 (0.51) | USP30GPR119 | |
| SCHEMBL4407107 | 0.81 | MAPK1 (0.44) | ESR2KRASNAMPTUSP30GPR119 | |
| SCHEMBL3277128 | 0.80 | RIPK1 (0.47) | TGFBR1ESR2NR1H2RIPK1USP30 | |
| SCHEMBL4410911 | 0.79 | GPR119 (0.39) | TGFBR1LMNATP53MAPTKRAS | |
| SCHEMBL24558105 | 0.78 | KRAS (0.40) | ESR2KRASUSP30 | |
| SCHEMBL24558408 | 0.78 | KRAS (0.40) | ESR2NR1H2KRASUSP30GPR119 | |
| SCHEMBL29693203 | 0.78 | KRAS (0.40) | ESR2KRASUSP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318412-A1 | Tricyclic heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318412-A1 | Tricyclic heterocyclic compound and use thereof | HTR2C, HTR2A, HTR5A | TGFBR1 2355/4885ESR2 1292/4885NR1H2 2084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.